Last reviewed · How we verify
Plasma-Lyte 148
Plasma-Lyte 148 is a marketed solution developed by The George Institute, currently holding a position in the electrolyte and fluid replacement market. A key strength of Plasma-Lyte 148 is its key composition patent, which is set to expire in 2028, providing a period of exclusive market protection. The primary risk facing Plasma-Lyte 148 is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Plasma-Lyte 148 |
|---|---|
| Also known as | Balanced multi-electrolyte solution, Balanced crystalloid solution |
| Sponsor | The George Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Precision Resuscitation With Crystalloids in Sepsis (NA)
- Descartes-08 in Autoantibody Myositis (PHASE2)
- Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis (PHASE3)
- Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) (PHASE2)
- Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression. (PHASE1, PHASE2)
- Effect of VExUS Ultrasound Protocol (Venous Excess Ultrasound) on Perioperative Fluid Management, on the Incidence of Postoperative Pulmonary Complications and Postoperative Acute Kidney Injury in Patients Undergoing Thoracic Surgery (NA)
- A Trial of Vigil for Participants With Ovarian Cancer (PHASE2)
- Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plasma-Lyte 148 CI brief — competitive landscape report
- Plasma-Lyte 148 updates RSS · CI watch RSS
- The George Institute portfolio CI